Evidence map›Paper›PMID 34865209›Full record

ArticleThrombosis and haemostasis2022

Predictive Modeling Identifies Total Bleeds at 12-Weeks Postswitch to N8-GP Prophylaxis as a Predictor of Treatment Response.

Pratima Chowdary, Kingsley Hampton, Victor Jiménez-Yuste, Guy Young, Soraya Benchikh El Fegoun, Aidan Cooper, Erik Scalfaro, Andreas Tiede

Open access · hybridAbstract read
In one paragraph

Article in Thrombosis and haemostasis, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers, 2 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
4citing papers in PubMed, 2 pooled it
0.3field-weighted citation impact, top 40% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

4 citing papers in PubMed, 2 syntheses or guidelines pooled it, 5 citations in OpenAlex.

  1. Pooled it
  2. Pooled it
  3. Observational
  4. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors at 7 institutions in 5 countries.

Pratima ChowdaryKatharine Dormandy Haemophilia and Thrombosis Centre, Royal Free Hospital, London, United Kingdom.ORCID 0000-0002-6690-8586
Kingsley HamptonDepartment of Cardiovascular Science, University of Sheffield, Sheffield, United Kingdom.
Victor Jiménez-YusteDepartment of Hematology, La Paz University Hospital-IdiPaz, Autónoma University, Madrid, Spain.
Guy YoungHemostasis and Thrombosis Center, Cancer and Blood Disorders Institute, Children's Hospital Los Angeles, University of Southern California Keck School of Medicine, Los Angeles, California, United Sates.
Soraya Benchikh El FegounGlobal Medical Affairs Biopharm, Novo Nordisk Health Care AG, Zürich, Switzerland.
Aidan CooperPredictive Analytics, Real World Solutions, IQVIA, London, United Kingdom.
Erik ScalfaroReal World Insights, IQVIA, Basel, Switzerland.
Andreas TiedeDepartment of Hematology, Hemostasis, Oncology and Stem Cell Transplantation, Hannover Medical School, Hanover, Germany.ORCID 0000-0002-3600-8536
Hospital Universitario La Paz · ESIQVIA (United Kingdom) · GBMedizinische Hochschule Hannover · DENovo Nordisk (Switzerland) · CHThe Royal Free Hospital · GBUniversity of Sheffield · GBUniversity of Southern California · US

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundPredicting annualized bleeding rate (ABR) during factor VIII (FVIII) prophylaxis for severe hemophilia A (SHA) is important for long-term outcomes. This study used supervised machine learning-based predictive modeling to identify predictors of long-term ABR during prophylaxis with an extended half-life FVIII.

methodsData were from 166 SHA patients who received N8-GP prophylaxis (50 IU/kg every 4 days) in the pathfinder 2 study. Predictive models were developed to identify variables associated with an ABR of ≤1 versus >1 during the trial's main phase (median follow-up of 469 days). Model performance was assessed using area under the receiver operator characteristic curve (AUROC). Pre-N8-GP prophylaxis models learned from data collected at baseline; post-N8-GP prophylaxis models learned from data collected up to 12-weeks postswitch to N8-GP, and predicted ABR at the end of the outcome period (final year of treatment in the main phase).

resultsThe predictive model using baseline variables had moderate performance (AUROC = 0.64) for predicting observed ABR. The most performant model used data collected at 12-weeks postswitch (AUROC = 0.79) with cumulative bleed count up to 12 weeks as the most informative variable, followed by baseline von Willebrand factor and mean FVIII at 30 minutes postdose. Univariate cumulative bleed count at 12 weeks performed equally well to the 12-weeks postswitch model (AUROC = 0.75). Pharmacokinetic measures were indicative, but not essential, to predict ABR.

conclusionCumulative bleed count up to 12-weeks postswitch was as informative as the 12-week post-switch predictive model for predicting long-term ABR, supporting alterations in prophylaxis based on treatment response.

Indexed as

Hemophilia AHemostaticsFactor VIIIHalf-LifeHemorrhageHumansFactor VIIIHemostatics

Identifiers

PMID34865209
PMCPMC9251711
OpenAlexW4200432605

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.